TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced its participation in the Emerging Growth Conference scheduled for August 18, 2021, at 12:00 PM. This online event allows shareholders and investors to engage directly with CEO Gerald Commissiong.

The conference is designed for public companies to showcase products and services, aiming to attract individual and institutional investors. Todos Medical specializes in diagnostic solutions for cancer, including proprietary blood tests, and recently acquired Provista Diagnostics to enhance its offerings.

Todos Medical (OTCQB: TOMDF) has received a notice of allowance from the USPTO for its Tollovid™ trademark, enhancing its market position for the product. Tollovid, a potent botanical 3CL protease inhibitor, aims to support immune function. The FDA granted a Certificate of Free Sale for Tollovid's 5-day regimen in April. The company plans to market Tollovid and Tollovid Daily™ in the U.S. starting August 2021, addressing a growing demand for immune support products. Todos is committed to regulatory compliance and aims to provide data supporting its product claims while developing diagnostic tests for various diseases.

Todos Medical (OTCQB: TOMDF) announced it received a notice of allowance for its Tollovid™ trademark from the USPTO, highlighting market interest in its 5-day high dose regimen designed to support healthy immune function. The product, a 3CL protease inhibitor, previously received a Certificate of Free Sale from the FDA. The company is finalizing marketing strategies for Tollovid and Tollovid Daily, enhancing its distribution through retail partners like The Alchemist Kitchen. CEO Gerald Commissiong expressed optimism regarding the growing demand for 3CL protease inhibitors in the market.

Todos Medical, Ltd. (OTCQB: TOMDF) completed its $10 million acquisition of Provista Diagnostics, making the final $1.25 million payment. Provista specializes in COVID-19 PCR testing and owns the Videssa breast cancer blood test. Todos is enhancing Provista's marketing efforts and has invested $2 million to upgrade its testing facilities. The company anticipates that its EUA approved cPass neutralizing antibody test will play a key role as COVID variants emerge. Todos aims to centralize its diagnostic platforms and drive growth through these strategic initiatives.

Todos Medical Ltd. (OTCQB: TOMDF) has retained Innvocept Global Solutions to manage two adaptive design Phase 2/3 clinical trials of its antiviral drug candidate Tollovir™ for treating COVID-19 patients in India. Enrollment for these trials is set to begin in Q3 2021, with initial data expected by Q4 2021, potentially contributing to global pivotal development. The dual-trial strategy aims to enhance recruitment and compare Tollovir's efficacy against evolving standards of care, as well as address the Delta variant's impact.

Todos Medical, Ltd. (OTCQB: TOMDF) announced FDA approval for its new dietary supplement, Tollovid Daily™, designed for twice-a-day dosing to support immune health. This product features a 3CL protease inhibitor claim and is part of a strategy to launch a monthly subscription model. The company expects significant revenue generation from the Tollovid product line by Q4 2021, leveraging the growing market for immune support supplements projected to reach over $31 billion by 2028. The product will be available for purchase soon, with initial stock already produced.

Todos Medical (OTCQB: TOMDF) has entered a distribution agreement with Fosun Pharma for the cPass SARS-CoV-2 Neutralizing Antibody Detection Kit, which has Emergency Use Authorization from the FDA. Recent research published in Nature Medicine highlights the importance of neutralizing antibodies in combating COVID-19 infections, including variants like Delta. Todos is validating the cPass test in its Provista Diagnostics lab, offering it as a service and distributing kits to client labs. The company sees a significant market opportunity for cPass as it ramps up sales and marketing efforts to capture a share of the growing COVID-19 testing market.

Todos Medical (OTCQB: TOMDF) announced the appointment of Ilanit Halperin, CPA, as Corporate Controller, aiming to enhance financial controls amid its growth strategy. With over 25 years of accounting experience, Halperin previously led the High-Tech and Life Sciences Department at Grant Thornton Israel. CFO Daniel Hirsch expressed confidence in her ability to strengthen financial infrastructure for future engagement with investors. The company also invited participation in its presentation at the Emerging Growth Conference on July 7, 2021, highlighting its focus on growth and compliance.

Todos Medical, Ltd. (OTCQB: TOMDF) provided a corporate update on June 29, 2021, highlighting progress on its COVID-19 antiviral, Tollovir, currently in Phase 2 trials in Israel with plans to expand to India. The company is also focusing on international distribution for its dietary supplement Tollovid. Todos is prioritizing proprietary diagnostic programs like Videssa for breast cancer and LymPro for Alzheimer’s as part of its Nasdaq listing strategy. With a focus on increasing sales through its Provista Diagnostics CLIA lab, Todos aims for substantial revenue growth by diversifying into higher-margin testing services.